PSMA-Targeted Therapy & Radiodiagnostics Competitor Analysis Report 2025 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Competitor Analysis: PSMA-Targeted Therapy & Radiodiagnostics" report has been added to ResearchAndMarkets.com's offering.

This competitive intelligence report about PSMA-Targeted Therapies & Radiodiagnostics provides a competitor evaluation in the field of product candidates in research and development targeting prostate-specific membrane antigen (PSMA). The report lists PSMA-targeted R&D programs by R&D phase in a tabular format and describes in brief the profile of PSMA-targeted therapies or radiodiagnostics by drug modality.

Prostate specific membrane antigen (PSMA) expression is prevalent in prostate cancer, preserved during malignant transformation, and increases in response to anti-androgen therapies, making it a commonly targeted tumor associated antigen for prostate cancer.

PSMA mainly serves as a binding target for delivery of a variety of payloads, including, but not limited to, cytotoxic drugs in antibody-drug conjugates, recruitment of cytotoxic T-cells in bispecific antibodies or directly PSMA-targeted chimeric antigen receptor T-cells or natural killer cells.

PSMA is also an important binding target for delivery of radioactive payloads in targeted radioligand therapy, whereby binding molecules can be small molecules, peptides and antibodies. A variety of radioligands are being evaluated or have already been approved, including lutetium 177, actinium 225, lead 212, cupper 67, terbium 161, and astatine 211.

PSMA-targeting is a clinically validated and increasingly commercially successful approach for positron emission tomography (PET) of prostate cancer and for treatment of PSMA-positive metastatic castration-resistant prostate cancer:

• With 2024 sales of US$ 1,058 mln (+24.3% vs 2023), the fluorinated PSMA-targeted PET imaging agent PYLARIFY exceeds US$ 1 billion in net sales and became the first ever blockbuster radiodiagnostic.
• PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) is a radioligand therapeutic agent. Lutetium Lu 177 vipivotide tetraxetan is a PSMA-binding ligand bound to a DOTA chelator radiolabeled with lutetium-177. Pluvicto posted 2024 sales of US$ 1,392 mln (+42% vs 2023).

For more information about this report visit https://www.researchandmarkets.com/r/sm0joe

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.